| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5097 | Tezosentan | Novel endothelin (ET) receptor antagonist |
|
| DCC5098 | Tfah-10n | Novel multipotent anti-Alzheimer agent, selectively inhibiting human butyrylcholinesterase (BChE), having strong antioxidant activity and good β-amyloid (Aβ) anti-aggregation properties |
|
| DCC5099 | Tfgf-18 | Novel GSK-3β inhibitor, showing anti-neuroinflammatory effects in lipopolysaccharide (LPS) activation of spontaneously immortalized SIM-A9 microglial cells and of mouse cortical microglia, inhibiting LPS-induced production of nitric oxide and the proinfla |
|
| DCC5100 | Tfmo-1 | Novel cell-active, selective class IIa HDAC inhibitor |
|
| DCC5101 | Tfmo-12 | CNS-penetrant selective class IIa histone deacetylase (HDAC) inhibitor, exploiting the >100-fold selectivity over class I/IIb HDACs |
|
| DCC5102 | Tfr4oht | Cyclized tamoxifen analog, selective ER modulator (SERM) |
|
| DCC5103 | Tg-0054 | Novel and Potent Stem Cell Mobilizer; Inhibitor of SDF-1α/CXCR4 binding |
|
| DCC5104 | Tg-0205221 | Novel potent SARS coronavirus (CoV) 3CL protease inhibitor (Ki = 53 nM) |
|
| DCC5105 | Tg100948 | Novel dual VEGFR/Src kinase inhibitor |
|
| DCC5106 | Tg101114 | Novel inhibitor of T315I mutant enzyme, exhibiting reasonable in vivo efficacy in a xenograft mouse model harboring T315I |
|
| DCC5107 | Tg11-77 Hydrochloride | Novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist |
|
| DCC5108 | Tg-2112x | Novel inhibitor of mitochondrial calcium uptake (#333333; font-family: "Open Sans", HelveticaNeue, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: |
|
| DCC5109 | Tg2-in-3h | Highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (TG2) inhibitor |
|
| DCC5110 | Tg3-95-1 | EP2 allosteric potentiator |
|
| DCC5111 | Tg4-166 | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC5112 | tg4-290-1 | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC5113 | tg4-292-1 | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC5114 | Tg4-294-2 | Potent and Selective Antagonist for Human EP2 Receptors |
|
| DCC5115 | Tgp-200c | Novel potent and structure-specific inhibitor of pre-miR-200c, reversing a type 2 diabetes phenotype |
|
| DCC5116 | Tgr5 Agonist 11d-na | Novel potent TGR5 agonist, displayind a significant glucose-lowering effect and stimulated GLP-1 and insulin secretion in TGR5H88Y mice but not in wild-type animals |
|
| DCC5117 | Tgr5-agonist-17 | Novel Potent Agonist of TGR5 Receptor |
|
| DCC5118 | Tgx-115 | Cell-permeable, potent, and selective inhibitor of PI 3-K isoforms p110ß/p110d |
|
| DCC5119 | Tgx-155 | Potent and selective inhibitor of PI 3-K |
|
| DCC5120 | Th1027 | Novel highly potent and specific inhibitor of TLR8, targeting an unconventional pocket on the TLR8 protein-protein Interface |
|
| DCC5121 | Thaigranatin T | Natural potent human carboxylesterase 2 (hCES2) inhibitor (IC50: 5.05 μM) |
|
| DCC5122 | Thalassosamide | Natural antibiotic, being active against P. aeruginosa both in vitro and in vivo. |
|
| DCC5123 | Thdp-17 | Novel glutaminase activity inhibitor, showing a partial uncompetitive inhibition in vitro and a significant reduction of ammonia and glutamate production in vivo |
|
| DCC5124 | Thiamphenicol Palmitate | Prodrug of Thiamphenicol, inhibiting the 50S subunit of the bacterial ribosome and protein translation |
|
| DCC5125 | Thiazolidinedione-8 | Novel antibiofilm agent, disturbing symbiotic balance between C. albicans and S. mutans in dual species biofilm |
|
| DCC5126 | Thidiazuron | Highly efficient bioregulator of plant morphogenesis in the tissue culture technique, inducing diverse responses ranging from induction of callus to embryogenesis or organogenesis, acting through modulation of the endogenous plant growth regulators, modif |
|
